key: cord-0895542-pkphlban authors: Martín, Julia; Tena, Noelia; Asuero, Agustin G. title: Current state of Diagnostic, Screening and Surveillance Testing Methods for COVID-19 from an Analytical Chemistry Point of View date: 2021-04-19 journal: Microchem J DOI: 10.1016/j.microc.2021.106305 sha: c27895eecf1e1c973d788de6d24c36be50179523 doc_id: 895542 cord_uid: pkphlban Since December 2019, we have been in the battlefield with a new threat to the humanity known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this review, we describe the four main methods used for diagnosis, screening and/or surveillance of SARS-CoV-2: Real-time reverse transcription polymerase chain reaction (RT-PCR); chest computed tomography (CT); and different complementary alternatives developed in order to obtain rapid results, antigen and antibody detection. All of them compare the highlighting advantages and disadvantages from an analytical point of view. The gold standard method in terms of sensitivity and specificity is the RT-PCR. The different modifications propose to make it more rapid and applicable at point of care (POC) are also presented and discussed. CT images are limited to central hospitals. However, being combined with RT-PCR is the most robust and accurate way to confirm COVID-19 infection. Antibody tests, although unable to provide reliable results on the status of the infection, are suitable for carrying out maximum screening of the population in order to know the immune capacity. More recently, antigen tests, less sensitive than RT-PCR, have been authorized to determine in a quicker way whether the patient is infected at the time of analysis and without the need of specific instruments. 284 Once the process is completed, a new double-stranded DNA target is obtained. To amplify 285 this genetic material, it is necessary to repeat cyclically the steps (ii-iv). In general, 30-45 286 cycles of PCR are needed to detect the virus. Amplification is the limiting factor to 287 transform the standard method into a rapid test, but it is thanks to this process that RT-PCR 288 has such a good sensitivity. The virus genome is detected by a fluorescence signal. A probe 289 is used for this purpose. The probe is a strand [20, 25, 45, 99] with a fluorophore at the 5' end 380 could be used as screening tool and the sequence of (RdRp) or the N gene could be used 381 simultaneously to confirm the infection. The nucleocapsid gene for protein N is stable and its sequences are maintained in time, 850 CLIAs are also used for quantitative antibody detection and have high sensitivity and 851 specificity. CLIA is similar to ELISA, though the antibody bound to the substrate is 852 detected by luminescence (Figure 4 ). More specifically, CLIAs usually apply an enzyme-853 catalyzed substrate, such as luminol, whereas ELISAs usually employ 3,3 ′ ,5,5 ′ -854 tetramethylbenzidine. In addition, CLIA shows higher sensitivity than ELISA and the 855 laboratory process is fully automated so that hundreds of samples can be screened per day 872 and specificities. These results showed that the serum testing using ELISA and CLIA were 873 more reliable, while the LFIA results should be considered with caution. However, this last 874 showed the advantage that can be performed at home without the need of any expert. In the 875 same study, Kontou et al. [167] also demonstrated that those tests using the S antigen are 876 more sensitive than N antigen-based tests, and that combined IgG/IgM test seems to be a 877 better choice in terms of sensitivity than measuring either antibody alone. 878 Overall, test accuracy varies for diagnostics from different manufacturers. It is commonly 879 measured in terms of sensitivity (production of positive results) and specificity (production 880 of negative results). However, these ranges could be improved depending on multiple factors mentioned above at 435 present, the RT-PCR method cannot be performed directly at POC because specific 436 installations, specialized instrumentation and personnel, and considerable analysis time are RT-PCR. Thus, four 460 different groups are presented: (i) RT-PCR in one step, (ii) Isothermal Amplification 461 termed RT-LAMP (Reverse Transcription PCR Loop-mediated isothermal AMPlification) step single-tube nested Furthermore, the efficiency throughout the period of infection has not been studied yet Isothermal Amplification (RT-LAMP) Thus, they are sensitive enough for cases with low RT-PCR cycle threshold (Ct <25) Antigen tests have been widely used to detect infection with viruses other than SARS-CoV Figure 3 and Table 4 show a chest X-ray and a chest CT, respectively 757 advanced, severe, and dissіpation according to the extent of the lesions (Table 4) [1]. to SARS-CoV-2 in the infected host organism, and the assays can detect 813 immunoglobulins A, M and G (IgA, IgM and IgG) usually in blood, plasma or serum recent reviews 209] use an anti-spike antibody binding to SARS-CoV-2 AuNPs attached to the antibodies, biomolecules, proteins, and aptamers can also increase 1009 the LSPR and SERS (surface enhanced Raman spectroscopy) signals, and the energy 1010 transfer between the fluorophore and AuNPs. A number of nanomaterial-based biosensors 1011 allows, actually, the detection of SARS-CoV-2 and related viruses 210] applied a dual-functional plasmonic biosensor utilizing plasmonic 1013 photothermal (PPT) effect and LSPR sensing transduction for the detection of various viral 1014 sequences genes from SARS-CoV-2. The aforementioned device is able to distinguish 1015 between SARS-CoV and SARS-CoV-2 viruses. The sensor shows a LOD of 0.22 pM. 1017 flow immunoassay (SERS-LFIA) to detect IgM and IgG simultaneously. To fabricate 1018 SERS, tags are modified with dual-layers of Raman dye, Silica core is completely coated 1019 with silver shell (SiO 2 @Ag), which shows superb SERS signal, decent monodispersity, 1020 and excellent stability Colorimetric biosensors have also found an use to detect SARS-CoV-2. These biosensors 1024 show interesting properties such as rapid response, accuracy and cost-effectiveness ASOs) for the specific detection of N-gene from nasal swab. The test allows detecting 1027 SARS-CoV-2 infection within 10 minutes. The detection mechanism involves the 1028 agglomeration of Au-ASOs architecture with target SARS-CoV-2 RNA, leading to red-1029 shift. The cleavage of RNA strands from RNA-DNA Ribonuclease H), a precipitate is finally obtained in the solution due to the 1031 additional agglomeration of AuNPs, being visible to naked-eye. The biosensor shows a 1032 LOD of 0.18 ng/mL for SARS-CoV-2 RNA and no cross-reactivity being apparent with 1033 MERS-CoV viral RNA Altogether, it is evident that up to now neither methods are ideal approaches for COVID The need for fast, transportable, low-cost, easy-to-use, decentralized, and high-frequency broad categories, laboratory tests (ELISA or CLIA) and POC tests 1076 (LFIA) The role of imaging 1108 in 2019 novel coronavirus pneumonia (COVID-19) A 1111 Diagnostic Challenge COVID-19 1114 transmission, current treatment, and future therapeutic strategies Air, surface environmental, and personal protective equipment 1118 contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1119 from a symptomatic patient Aerosol and 1123 surface stability of SARS-CoV-2 as compared with SARS-CoV-1 Detection of SARS-CoV-2 1126 in different types of clinical specimens A familial cluster of infection associated 1129 with the 2019 novel coronavirus indicating potential person-to-person transmission 1130 during the incubation period Diagnostic methods and potential portable biosensors for 1133 coronavirus disease 2019 Automated detection of COVID-19 cases using deep neural networks with X-ray 1139 images Opportunities and challenges for biosensors 1142 and nanoscale analytical tools for pandemics: COVID-19 Positive rate of RT-1145 PCR detection of SARS-CoV-2 infection in 4880 cases from Novel one-step single-tube nested quantitative real-time PCR assay for highly 1150 sensitive detection of SARS-CoV-2 CoroNet: A deep neural network for detection 1153 and diagnosis of COVID-19 from chest x-ray images Serology testing in the COVID-19 pandemic 1157 response Molecular and antibody 1160 point-of-care tests to support the screening, diagnosis and monitoring of COVID-1161 19. The Centre for Evidence-Based Medicine develops, promotes and disseminates 1162 better evidence for healthcare 2020 A facile assay for rapid detection of COVID-19 antibodies Evaluation of nucleocapsid and spike protein-based enzyme-linked 1169 immunosorbent assays for detecting antibodies against SARS-CoV-2 An analysis of 38 pregnant women with COVID-19, their newborn 1172 infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus 1173 infections and pregnancy outcomes Systematic review of artificial intelligence techniques in the detection and 1178 classification of COVID-19 medical images in terms of evaluation and 1179 benchmarking: Taxonomy analysis, challenges, future solutions and 1180 methodological aspects COVID-19 diagnostic testing: Technology perspective Biomarkers of COVID-19 and technologies to combat SARS-CoV-1186 Nucleic acid testing 1188 for coronavirus disease 2019: Demand, research progression, and perspective Diagnostic techniques for COVID-1191 19 and new developments Comprehensive review on current interventions, diagnostics, and nanotechnology 1195 perspectives against SARS-CoV-2 Detection of COVID-19: A review of the current literature and 1199 future perspectives Laboratory diagnosis of coronavirus 1202 disease-2019 (COVID-19) Detecting the coronavirus (COVID-19) Diagnostics for SARS-CoV-2 detection: 1207 A comprehensive review of the FDA-EUA COVID-19 testing landscape Current and perspective diagnostic techniques for COVID-19 The vision of point-of-1213 care PCR tests for the COVID-19 pandemic and beyond Point-of-care diagnostics of 1216 COVID-19: From current work to future perspectives COVID-19 Clinical Diagnostics and Testing 1219 Technology Breath analysis for detection of 1222 viral infection, the current position of the field Towards effective diagnostic assays for COVID-19: A review Testing for 1227 SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and 1228 serological in-vitro diagnostic assays Coronavirus Disease 1232 2019-COVID-19 Molecular diagnosis of COVID-19: Challenges and 1236 research needs The laboratory's role in combating COVID-19 Diagnosing COVID-19: 1242 The Disease and Tools for Detection Challenges in laboratory diagnosis of the novel 1246 coronavirus SARS-CoV-2 The diagnostic methods in the COVID-19 1249 pandemic, today and in the future Overcoming 1252 the bottleneck to widespread testing: a rapid review of nucleic acid testing 1253 approaches for COVID-19 detection Molecular and serological assays for SARS-1256 CoV-2: insights from genome and clinical characteristics Assay techniques and 1260 test development for COVID-19 diagnosis Laboratory Diagnosis of Novel 1263 Coronavirus Disease 2019 (COVID-19) Infection A Review of Salivary 1267 Diagnostics and Its Potential Implication in Detection of COVID-19 In vitro diagnostic assays for COVID-19: Recent advances and 1270 emerging trends Novel coronavirus disease (COVID-19): 1272 Paving the road for rapid detection and point-of-care diagnostics Laboratory diagnosis of emerging human coronavirus 1275 infections -The state of the art The appropriate use of testing for COVID-19 Recent 1280 advances and perspectives of nucleic acid detection for coronavirus Recent advances in the detection of respiratory virus infection in Can 1320 nanotechnology help in the fight against COVID-19? Biosafety materials: an emerging new research direction of materials science from 1324 the COVID-19 outbreak Development of Point-of-Care Biosensors for COVID-19 A review of mathematical modeling, 1329 artificial intelligence and datasets used in the study, prediction and management of 1330 COVID-19 Approaches based on artificial intelligence and 1333 the internet of intelligent things to prevent the spread of COVID-19: Scoping 1334 Review Molecular bases of 1336 COVID-19 pathogenesis The 1339 COVID-19 pandemic COVID-19 pandemicda focused review for 1342 clinicians COVID-19): A literature 1346 review COVID-19 and the clinical 1349 hematology laboratory SARS-CoV-2 and acute respiratory syndrome 1352 pandemic (COVID-19) Contribution of the biomedical sciences in the state of alarm 1355 caused by the SARS-CoV-2 virus pandemic Novel coronavirus (COVID-19) outbreak: A Review of 1359 the current literature World Health Organization declares global emergency: A review of the 2019 1363 novel coronavirus (COVID-19) Emerging coronaviruses: Genome structure, replication, and 1366 pathogenesis COVID-19: Pathophysiology, 1368 treatment options, nanotechnology approaches, and research agenda to combating 1369 the SARS-CoV-2 pandemic Current status of 1372 COVID-19 (pre)clinical vaccine development Current perspective 1375 of antiviral strategies against COVID-19 COVID-19: Drug targets and potential 1379 treatments Crucial laboratory parameters in COVID-19 diagnosis and 1382 prognosis: An updated meta-analysis 1385 Nanotechnology for COVID-19: Therapeutics and vaccine research COVID19: A Systematic Approach to Early Identification and 1389 Nature as a treasure trove of potential anti-SARS-CoV drug 1393 leads: a structural/mechanistic rationale Real-time RT-PCR in COVID-19 detection: issues 1396 affecting the results World Health Organization. Laboratory testing for coronavirus disease (COVID-19) 1399 in suspected human cases. Interim guidance 19 March 2020 World Health 1400 Organization Virological assessment of 1403 hospitalized patients with COVID-2019 Detection and analysis 1406 of nucleic acid in various biological samples of COVID-19 patients Clinical Samples for SARS-CoV-2 Detection: Review of the early 1409 literature The impacts of viral inactivating 1412 methods on quantitative RT-PCR for COVID-19 Heat 1415 inactivation decreases the qualitative real-time RT-PCR detection rates of clinical 1416 samples with high cycle threshold values in COVID-19 Potential false-1419 negative nucleic acid testing results for Severe Acute Respiratory Syndrome 1420 Coronavirus 2 from thermal inactivation of samples with low viral loads Multifunctional nano-magnetic particles assisted viral RNA-extraction 1424 protocol for potential detection of COVID-19 Massive and rapid COVID-19 testing is feasible by extraction-free SARS CoV-2: Comparative analysis of different RNA extraction methods COVID-19 diagnosis -A review of current 1435 methods Molecular diagnostic technologies for COVID-19: Limitations and 1438 challenges Diagnostics for SARS-CoV-2 infections Epidemiological 1443 Update: Variants of SARS-CoV-2 in the Americas PAHO/WHO; 2021 Comparative analysis of primer−probe sets for RT-qPCR 1448 of COVID-19 causative virus (SARS-CoV-2) Distinct changes in the real-time PCR detectability of certain 1451 SARS-CoV-2 target sequences Evaluación de diferentes genes en la detección por RT-PCR del 1454 SARS-CoV-2 en muestras respiratorias y su evolución en la infección Viral Disease Control Institute Viral RNA load as determined by cell culture as a management tool for discharge 1461 of SARS-CoV-2 patients from infectious disease wards Duration of severe acute respiratory 1464 syndrome coronavirus 2 (SARS-CoV-2) infectivity: when is it safe to discontinue 1465 isolation? Epidemiologic features and clinical course of patients infected with SARS-CoV-2 1468 in Singapore College of American Pathologists (CAP) Microbiology Committee 1474 Perspective: Caution must be used in interpreting the Cycle Threshold et 1477 al. Virological assessment of hospitalized patients with COVID-2019 Prevention: duration of isolation and precautions for 1480 adults with COVID-19 COVID-19: A PCR-defined pandemic Highly sensitive detection of SARS-CoV-2 1486 RNA by multiplex rRT-PCR for molecular diagnosis of COVID-19 by clinical 1487 laboratories Photonic toolbox for fast real-time polymerase chain reaction Rapid detection of novel 1493 coronavirus/Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by 1494 reverse transcription-loop-mediated isothermal amplification Smartphone-based multiplex 1498 30-minute nucleic acid test of live virus from nasal swab extract 1501 Development of reverse transcription loop-mediated isothermal amplification assays 1502 targeting Severe Acute Respiratory Syndrome Coronavirus Rapid 1505 Detection of COVID-19 Coronavirus Using a Reverse Transcriptional Mediated Isothermal Amplification (RT-LAMP) Diagnostic Platform Development of a Novel Reverse Transcription Loop-1509 Mediated Isothermal Amplification Method for Rapid Detection of SARS-CoV-2 A Single and Two-Stage, Closed-Tube, Molecular 1512 Test for the 2019 Novel Coronavirus (COVID-19) at Home, Clinic, and Points of 1513 Entry RT-LAMP for rapid diagnosis of coronavirus SARS-CoV-2 LAMP-Seq: Population-Scale COVID-19 Diagnostics using 1519 combinatorial barcoding bioRxiv (2020) 025635 DOI: 1520 CRISPR-Cas12-based 1523 detection of SARS-CoV-2 Rapid and sensitive detection of COVID-19 using CRISPR/Cas12a-1527 based detection with naked eye readout, CRISPR/Cas12a-NER Point-of-care testing for COVID-19 using 1531 SHERLOCK diagnostics. medRxiv Rapid and sensitive detection of SARS-1535 CoV-2 RNA using the Simplexa TM COVID-19 direct assay World Health Organization (2020) Antigen-detection in the diagnosis of SARS-1538 CoV-2 infection using rapid immunoassays: interim guidance Centers for Disease Control and Prevent (2020) Interim Guidance for Antigen 1541 Testing for SARS-CoV Comparison of automated 1546 SARS-CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 1547 313 nasopharyngeal swabs, including from seven serially followed patients Clinical validation of quantitative SARS-CoV-1551 2 antigen assays to estimate SARS-CoV-2 viral loads in nasopharyngeal swabs Rapid SARS-CoV-2 antigen detection by immunofluorescence -1555 a new tool to detect infectivity Accuracy of a nucleocapsid protein antigen rapid test in the diagnosis of 1559 SARS-CoV-2 infection Real-life 1563 validation of the PanbioTM COVID-19 antigen rapid test (Abbott) in community-1564 dwelling subjects with symptoms of potential SARS-CoV-2 infection LHUB-ULB SARS-CoV-2 1568 working diagnostic group Development and Potential Usefulness of the COVID-19 Importation and human-to-human transmission 1573 of a novel coronavirus in Vietnam A novel coronavirus from patients with pneumonia in China A rapid advice guideline for the diagnosis and treatment 1581 of Chest CT findings in coronavirus disease-19 (COVID-19): 1585 relationship to duration of infection Time course of lung changes on chest CT during recovery from 2019 1589 novel coronavirus (COVID-19) pneumonia Sensitivity of chest CT 1592 for COVID-19: comparison to RT-PCR Correlation 1595 of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: 1596 a report of 1014 cases Early screening of SARS-1599 CoV-2 by intelligent analysis of X-Ray images Deep learning COVID-Net: A Tailored deep convolutional neural 1604 network design for detection of COVID-19 cases from chest radiography images COVID-19: Automatic detection from X-Ray 1607 images utilizing transfer learning with convolutional neural networks Automatic detection of coronavirus disease Ray images and deep convolutional neural networks. (2020) arXiv 1611 preprint Detection of Coronavirus Disease 1613 (COVID-19) based on Deep Features and Support Vector Machine Deep learning 1616 enables accurate diagnosis of novel coronavirus (COVID-19) with CT images A deep learning algorithm 1620 using CT images to screen for Corona Virus Disease (COVID-19) Deep learning-based 1623 detection for COVID-19 from chest CT using weak label A review on smartphone skin cancer diagnosis apps in evaluation and 1627 benchmarking: coherent taxonomy, open issues and recommendation pathway 1628 solution Comprehensive 1630 insights into evaluation and benchmarking of real-time skin detectors: review, open 1631 issues & challenges, and recommended solutions Validation and performance 1635 comparison of three SARS-CoV-2 antibody Detection of antibodies against SARS-1638 CoV-2 in patients with COVID-19 Detection of antibodies against SARS-CoV-2 spike 1641 protein by gold nanospikes in an opto-microfluidic chip World Health Organization, Laboratory biosafety guidance related to coronavirus 1644 disease 2019 (COVID-19 The main molecular and serological methods for diagnosing COVI-19: an overview 1649 based on the literature The utility of specific antibodies against SARS-Cov-2 in 1651 laboratory diagnosis Global progresses on serology-based tests 1654 for COVID-19 Clinical usefulness of fully 1659 automated chemiluminescent immunoassay for quantitative antibody 1660 measurements in COVID-19 patients Evaluation of enzyme-1663 linked immunoassay and colloidal gold-immunochromatographic assay kit for 1664 detection of novel coronavirus (SARS-Cov-2) causing an outbreak of pneumonia 1665 Performance verification of detecting 1667 COVID-19 specific antibody by using four chemiluminescence immunoassay 1668 systems A peptide-based magnetic chemiluminescence enzyme immunoassay for 1672 serological diagnosis of corona virus disease 2019 (COVID-19) Analytical 1675 performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG 1676 and antibody kinetics Antibody tests 1679 in detecting SARS-CoV-2 infection: a meta-analysis Serological immunochromatographic approach in diagnosis with SARS-CoV-2 1683 Infected COVID-19 Patients A 1687 systematic review of antibody mediated immunity to coronaviruses: kinetics, 1688 correlates of protection, and association with severity COVID-19 antibody tests and their limitations Mass spectrometry-based 1693 structural virology Open science 1696 Resources for the Mass Spectrometry-Based Analysis of SARS-CoV-2 Saliva NMR-1699 based metabolomics in the war against COVID-19 Nanomaterials to tackle the COVID-19 pandemic Essential role of quantum science and 1704 nanoscience in antiviral strategies for COVID-19 Prospects of 1707 nanomaterials-enabled biosensors for COVID-19 detection Analysis of recent bio-1710 /nanotechnologies for coronavirus diagnosis and therapy Fortifying the diagnostic-frontiers with nanoscale 1713 technology amidst the COVID-19 catastrophe Nanotecnology based approaches for combating COVID-19 1716 viral infection 1719 SARS-CoV-2 vaccine strategies: a comprehensive review of phase 3 candidates Editorial: A glimmer of hope beyond the spring of Europe CRISPR systems for COVID-19 diagnosis CRISPR systems: novel approaches for detection and combating 1730 COVID-19 CRISP-based tools: alternative 1733 methods for the diagnosis of COVID-19 CRISP-Cas systems as 1736 potential rapid diagnosis tools for emerging infectious diseases Point-of-care 1739 testing detection methods for COVID-19 COVID-19 pandemic: review of contemporary and 1744 forthcoming detection tools Current methods for diagnosis 1747 of human coronaviruses: pros and cons Current advances in the detection of COVID-19 and 1750 evaluation of the humoral response Detection 1753 technologies and recent developments in the diagnosis of COVID-19 infection Optical technologies for the detection of 1757 viruses like COVID-19: Progress and prospects The perspectives of 1760 biomarker-based electrochemical immunosensors, artificial intelligence and the 1761 Internet of Medical Things toward COVID-19 diagnosis and management 1768 SERS based lateral flow immunoassay for point-of-care detection of SARS-CoV-2 1769 in clinical samples 5G-enabled 1771 ultra-sensitive fluorescence sensor for proactive prognosis of COVI-19 Remote diagnostic and detection of coronavirus disease (COVID-19) 1775 system based on intelligent healthcare and internet of things A smartphone-read ultrasensitive and quantitative 1778 saliva test for COVID-19 Amplification-free detection of SARS-1781 CoV-2 with CRISPR-Cas 13a and mobile phone microscopy Electrochemical sensing directions 1784 for next-generation healthcare: trends, challenges, and frontiers From diagnosis to 1787 treatment: recent advances in patient-friendly biosensors and implantable devices Biosensors as a future diagnostic approach for COVID-19 Emerging biosensing technologies for improved 1793 diagnostics of COVID-19 and future pandemics Current status, advances, challenges and 1796 perspectives on biosensors for COVID-19 in resource-limited setting Point of care detection of COVID-19: 1800 Advancement in biosensing and diagnostic methods COVID-19: A challenge for 1803 electrochemical biosensors Biosensors promising bio-device for pandemic screening 1806 "COVID-19 Development of a 1809 portable, ultra-rapid and ultra-sensitive cell-based biosensor for the direct detection 1810 of the SARS-CoV-2 S1 spike protein antigen Magnetic beads combined with carbon 1814 black-based screen-printed electrodes for COVID-19: a reliable and miniaturized 1815 electrochemical immunosensor for SARS-CoV-2 detection in saliva Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) 1819 in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based 1820 Dual-functional 1822 plasmonic photothermal biosensors for highly accurate severe acute respiratory 1823 syndrome coronavirus 2 detection Development of a SERS-1826 based lateral flow immunoassay for rapid and ultra-sensitive detection of anti-1827 SARS-CoV-2 IgM/IgG in clinical samples 1835 FIGURE CAPTIONS 1836 Figure 1. SARS-CoV-2 structure. Virus from the Coronaviridae family. The S protein 1837 mediates attachment of the virus to cellular receptors and virus entry by fusion with cell 1838 membranes. Both M and E proteins are integral membrane proteins and form the minimum 1839 protein units for virus assembly. The N protein is an extensively phosphorylated, highly 1840 basic protein Figure 2. Schematic diagram of sampling, extraction and purification of ARN, and 1842 molecular representation of RT-PCR Figure 3. Chest X-ray images of a 50-year-old COVID-19 patient with pneumonia over a 1844 week Schematic diagram of ELISA and CLIA for COVID-19 IgM/IgG antibodies 1846 Schematic diagram of the LFIA for COVID-19 IgM/IgG antibodies (taken from 1848 [21] with permission) Alkaline Phosphatase; aM, Attomolar Biosecurity 1926 Level; CAP, College of American 1927 Pathologists Clinical 1936 Laboratory Improvement 1937 Amendments Clustered Regularly Interspaced Short 1940 Palindromic Repeats; CT, Chest Cycle 1942 Threshold; DETECTR, SARS-1943 CoV-2 DNA Endonuclease-Targeted Dexosyrosyribonucleic Acid; dNTPs, 1946 Nucleotides; ddPCR, Droplet digital 1947 PCR; dPCR Envelope 1948 protein; ELISA, Enzyme Linked European Medicines Agency; EUA, 1951 Emergence Use Authorization FDA, Food and Drug Administration Effect Transistor; fM Genetic 1955 sequence data base of the National 1956 Institute of Health; GISAID, Global 1957 Initiative on Sharing All Influenza 1958 Data International Committee 1959 on Taxonomy of Viruses Internet 1963 of Medical Things; IoT, Internet 1964 of Things; LFIA, Lateral Flow Magnetic Nanoparticle; m-1972 RNA Nucleocapsid protein; NER, Naked 1975 Eye Readout; Net Next Generation Molecular Next Generation Sequencing Institute of Health; nM One Step Single-tube Nested Plaque-forming unit; pM, Picomolar RBD, Receptor-binding domain RNA-Dependent RNA 1988 Polymerase; rN, Recombinant 1989 nucleocapsid protein antigen Recombinant 1992 Spike protein antigen; R 0 , Basic 1993 reproductive number; RT, Reverse 1994 Transcriptase; RT-LAMP Polymerase Chain Reaction Complete 2005 silver nanoparticle shell coated on 2006 silica core; ssRNA, Single-Stranded 2007 Positive-Sense RNA; STOPCovid, 2008 SHERLOCK Testing on One Pot 2009 SVM Support Vector Machine; US 2010 CDC, US Centers for Disease Control Results show that they have an excellent sensitivity to detect the virus in samples with (Ct values ≤25), which are found in pre-symptomatic (1-3 days before symptom onset) and early symptomatic COVID-19 cases (5-7 days after symptom onset). In vitro experiments showed no viral growth from samples with Cts >24 or taken >8 days after symptom onset.However, the exact threshold of contagiousness is unknown at the moment. Additional studies with larger numbers of samples are needed. They need instrumentation.[133] mmunofluorescence assay consists of a itrocellulose membrane with fluorescent icroparticles-labeledThe results show high specificity and relative high sensitivity in the early phase of infection.[134] ARS-CoV-2 NP-specific antibody (mouse nti-SARS-CoV-2 NP M1). This antibody was roduced by vaccination of mice with long eptides containing the ARS-CoV-2 NP-specific epitopes. A doublentibody sandwich is formed, and a fluorescent ignal is detected if the sample contain the virus. he fluorescent results are read by an munofluorescence analyzer. Qualitative etection.However, the study does not include individuals without symptoms. It need instrumentation. mmunochromatographic assay consists of a embrane-based which detects the ucleocapsid protein of SARS-CoV-2 in asopharyngeal samples. Single lot of later flow nalysis (LFA) testing devices were used: lot 1ADF011A. ualitative detection.Results in 15 min. Study carried out extensively to determine the sensitivity of the LFA. The test has a sensitivity higher than 73% when samples from patients with symptoms for less than seven days are analysed. It does not need instrumentation.However, the test gave false negative results in patients with low viral load which may occur very early in the infection before viral replication peaks, or in a late stage of infection when replication has decreased after.[135] mmunochromatographic test consists of ipstick based on a membrane technology with olloidal gold nanoparticles using monoclonal ntibodies directed against SARS-CoV-2 ighly conserved nucleoprotein antigen. ualitative detection. However, sensitivity and specificity of 57.6 and 99.5%, respectively with an accuracy of 82.6%.[136] 1900 1901 1902